https://www.selleckchem.com/pr....oducts/nazartinib-eg
3% (258/1061). In the two validation groups hypoglycemia was measured in 269/2592 patients (11.1%); and 393/3635 (10.8%). AUROC was 0.72 (95% CI 0.68-0.76); and 0.71 (95% CI 0.68-0.74). In the highest probability groups hypoglycemia was measured in 28.1% (111/395); and 23.0% (211/909) of patients. The derived model performed well in the validation cohorts. Assuming that most of the hypoglycemia episodes could be prevented we would need to invest efforts to avoid hypoglycemia in 4-5 patients to prevent one episode of hy
Gefällt mir
Kommentar
Teilen
